Pharma and BioTech Daily

EXPLORE

Society & Culture

© 2024 PodJoint

https://is1-ssl.mzstatic.com/image/thumb/Podcasts211/v4/2e/6f/bd/2e6fbd0f-388e-86bf-3355-a306edd50f8d/mza_4523107895456280344.jpg/600x600bb.jpg

Pharma and BioTech Daily

Pharma and BioTech News

137 episodes

1 day ago

Send us a text Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a landscape marked by significant scientific advancements, regulatory approvals, and strategic shifts that are reshaping the industry.Starting with Regeneron, the company's ophthalmic drug Eylea HD has recently secured two FDA approvals. These endorsements not only grant a new indication but also introduce a more flexible dosi...

Show more...

All content for Pharma and BioTech Daily is the property of Pharma and BioTech News and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

Send us a text Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a landscape marked by significant scientific advancements, regulatory approvals, and strategic shifts that are reshaping the industry.Starting with Regeneron, the company's ophthalmic drug Eylea HD has recently secured two FDA approvals. These endorsements not only grant a new indication but also introduce a more flexible dosi...

Show more...

Episodes (20/137)

Pharma and BioTech Daily

Pharma Breakthroughs: FDA Approvals and mRNA Expansion

Send us a text Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a landscape marked by significant scientific advancements, regulatory approvals, and strategic shifts that are reshaping the industry.Starting with Regeneron, the company's ophthalmic drug Eylea HD has recently secured two FDA approvals. These endorsements not only grant a new indication but also introduce a more flexible dosi...

1 day ago

11 minutes

Pharma and BioTech Daily

Breakthroughs and Strategic Shifts in Pharma & Biotech

Send us a text Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into the intricate tapestry of scientific advancements, regulatory decisions, and strategic maneuvers shaping our industry.One of the notable stories involves Agios Pharmaceuticals, which is pushing forward with its sickle cell disease treatment, Pyrukynd, for FDA approval. This comes despite mixed results from their Phase 3 clinic...

2 days ago

13 minutes

Pharma and BioTech Daily

Pharma Breakthroughs: Regeneron, CSL, and Merck Lead

Send us a text Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into the dynamic landscape of the industry, exploring significant scientific advancements, regulatory changes, clinical trial outcomes, and strategic investments that are shaping the future of healthcare.Starting with strategic investments, Regeneron is making a bold move with a $2 billion investment to transform a former magazine ...

3 days ago

7 minutes

Pharma and BioTech Daily

Oncology Breakthroughs and Strategic Acquisitions Reshape Pharma

Send us a text Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a host of transformative events reshaping the landscape, from strategic acquisitions and funding infusions to regulatory maneuvers and scientific breakthroughs.Johnson & Johnson has taken a decisive step in its oncology strategy with the $3 billion acquisition of Halda's cell death technology. This acquisition, focusing on...

4 days ago

6 minutes

Pharma and BioTech Daily

Strategic Shifts and Breakthroughs in Pharma Innovation

Send us a text Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a myriad of pivotal changes and advancements that have been shaping our industry.The competitive nature of acquisitions within the biopharma sector has been exemplified by recent strategic buyouts. Lundbeck's decision to outbid Alkermes for Avadel Pharmaceuticals highlights how companies are leveraging acquisitions to expa...

5 days ago

4 minutes

Pharma and BioTech Daily

Revolutionizing Personalized Medicine: FDA's New Pathway

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into several groundbreaking advancements and strategic shifts in the industry that promise to reshape the landscape of patient care and therapeutic innovations.The U.S. Food and Drug Administration has introduced a novel regulatory pathway aimed at expediting the approval process for custom gene-editing therapies. Articulated by FDA officials...

1 week ago

6 minutes

Pharma and BioTech Daily

Revolutionizing Oncology: Pfizer's PD-1xVEGF Breakthrough

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of compelling updates that underscore the dynamic nature of our industry, marked by scientific breakthroughs, strategic shifts, regulatory advancements, and more.Starting with Pfizer's ambitious endeavors in oncology, the company has initiated Phase 3 trials for its bispecific antibody PF-08634404, targeting non-small cell lung canc...

1 week ago

6 minutes

Pharma and BioTech Daily

Strategic Acquisitions and Breakthrough Partnerships in Pharma

Good morning from Pharma Daily, the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of groundbreaking changes and innovations reshaping the landscape of drug development, clinical trials, and regulatory affairs.In a major move, Pfizer has successfully outbid Novo Nordisk to acquire Metsera for $10 billion. This strategic acquisition aims to bolster Pfizer's presence in the obesity treatment market by leveraging Met...

1 week ago

5 minutes

Pharma and BioTech Daily

Revolutionizing Drug Development: Key Breakthroughs and Strategic Moves

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. In today's rapidly evolving landscape, we witness significant strides shaping the future of drug development, patient care, and global market dynamics.Merck & Co. has made a notable advancement in cholesterol management with a PCSK9-targeted pill. This pill has achieved reductions in low-density lipoprotein cholesterol (LDL-C) comparable to existing injectab...

1 week ago

6 minutes

Pharma and BioTech Daily

FDA Milestones and Oncology Innovations: Key Industry Shifts

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of groundbreaking developments that are reshaping the landscape of drug development and patient care. These stories highlight the dynamic nature of the pharmaceutical and biotechnology industries, where scientific advancements and regulatory changes are driving significant shifts.We begin with a crucial milestone in oncology tre...

1 week ago

7 minutes

Pharma and BioTech Daily

Transformative Therapies: Innovations and Regulatory Shifts

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we explore a series of groundbreaking advancements and strategic collaborations that promise to transform drug development and patient care.In the autoimmune space, Boehringer Ingelheim has made a significant move by securing a $570 million agreement with CDR-Life. This deal centers on a trispecific antibody, a novel therapeutic approach that targets mult...

2 weeks ago

8 minutes

Pharma and BioTech Daily

**Industry Shifts: Mergers, Regulations, and Biotech Breakthroughs**

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of transformative events reshaping the landscape of healthcare, from strategic mergers and regulatory shifts to groundbreaking advancements in drug development.Let's begin with a monumental merger that signals a shift towards more integrated healthcare solutions. The $48.7 billion acquisition of Kenvue, a consumer health spinout...

2 weeks ago

8 minutes

Pharma and BioTech Daily

Precision Oncology and HIV Prevention Breakthroughs

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of fascinating advancements and strategic movements that are shaping the landscape of drug development and patient care.Starting with a significant milestone in precision oncology, China has approved its first EGFR-targeted antibody-drug conjugate. This approval marks a pivotal moment in the industry’s shift towards targeted the...

2 weeks ago

7 minutes

Pharma and BioTech Daily

Pharma Shifts: Dual-Action Obesity Drugs & Regulatory Waves

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today's focus is on a series of significant advancements that are poised to reshape the landscape of drug development, regulatory standards, and patient care.Eli Lilly has made remarkable strides with its dual-action obesity medications, Zepbound and Mounjaro. Despite being removed from the CVS formulary, these drugs have achieved exceptional sales figures, reac...

3 weeks ago

7 minutes

Pharma and BioTech Daily

Navigating Pharma's New Frontiers: Breakthroughs and Challenges

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're exploring a series of significant developments that underscore the rapid evolution within these industries.Starting with one of the major players, Merck, which has been strategically adjusting its focus in light of Keytruda's looming loss of exclusivity. The company has demonstrated remarkable progress with Welireg in kidney cancer trials, successfu...

3 weeks ago

6 minutes

Pharma and BioTech Daily

Gene Therapy Challenges and Regulatory Shifts: Industry Innovations

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a dynamic landscape of scientific breakthroughs, regulatory shifts, and strategic maneuvers reshaping the industry.BioMarin's recent decision to divest from its hemophilia A gene therapy, Roctavian, has garnered significant attention. Despite being the sole approved gene therapy for hemophilia A, Roctavian has struggled with sales since its ...

3 weeks ago

8 minutes

Pharma and BioTech Daily

Biotech Breakthroughs: Transformative Acquisitions and FDA Milestones

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into several significant shifts in the industry, marked by scientific advancements, regulatory changes, and strategic corporate maneuvers.Starting with a major acquisition, Novartis has strategically purchased Avidity Biosciences, a San Diego-based biotech company specializing in muscular dystrophy treatments, for a striking $12 billion. This...

3 weeks ago

5 minutes

Pharma and BioTech Daily

Novartis' $12B RNA Therapeutics Breakthrough

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into some of the most significant shifts and strategies shaping our industry.Novartis’s acquisition of Avidity Biosciences for a staggering $12 billion marks a pivotal moment in the pharmaceutical landscape this year. With this acquisition, Novartis underscores its commitment to bolstering its neuromuscular disease pipeline. Avidity Biosciences h...

3 weeks ago

5 minutes

Pharma and BioTech Daily

Week in Review - October 25, 2025

This week in review covers 5 episodes from October 20 to October 24, featuring major developments in pharmaceutical and biotech industries including strategic acquisitions, regulatory updates, and clinical trial results. Episodes included: 1. Pharma Innovations: AI's Impact and Strategic Shifts 2. Strategic Acquisitions and AI Revolutionize Pharma Landscape 3. Industry Shifts: Novo Nordisk's Revamp & ADC Breakthroughs 4. Transformative Advances in Precision Oncology and ADCs 5. Transforma...

4 weeks ago

31 minutes

Pharma and BioTech Daily

Pharma Innovations: AI's Impact and Strategic Shifts

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving deep into a series of significant events that are shaping the future of drug development and patient care.Starting with Merck KGaA, their decision to close the Active Pharmaceutical Ingredient plant in Arklow, Ireland by 2028 marks a pivotal shift in their manufacturing strategy. This move follows a strategic review and is emblematic of broad...

4 weeks ago

6 minutes